Welcome to our dedicated page for Arcus Bioscience news (Ticker: RCUS), a resource for investors and traders seeking the latest updates and insights on Arcus Bioscience stock.
Arcus Biosciences, Inc. reports developments as a clinical-stage global biopharmaceutical company developing differentiated molecules and combination therapies for cancer and inflammatory and autoimmune diseases. Company news commonly covers quarterly financial results, pipeline updates, clinical program strategy, data presentations and changes in research priorities across its investigational portfolio.
Recurring updates focus on casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma, quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer, and earlier inflammation programs such as AB102, an MRGPRX2 antagonist. Arcus also issues routine corporate announcements on employment inducement grants, investor conference participation and collaboration-related developments.
Arcus Biosciences (NYSE:RCUS) reported first-quarter 2026 results and a pipeline update. Key items: $876M in cash and equivalents at March 31, 2026 with runway to at least H2 2028; expected year-end 2026 cash of ~$600M. Casdatifan development is prioritized with PEAK-1 enrollment and a planned 1L Phase 3 start by year-end 2026. AB102 (MRGPRX2 antagonist) is expected to enter the clinic in Q3 2026. PRISM-1 topline results for quemliclustat are expected in H1 2027. Net loss was $128M in Q1 2026; revenue guidance for 2026 is $50–65M.
Arcus Biosciences (NYSE:RCUS) announced employment inducement equity awards on April 24, 2026. The Compensation Committee granted options to purchase 4,200 shares at an exercise price of $25.13 (April 23, 2026 close) and 2,100 restricted stock units. Awards were granted under the company’s 2020 Inducement Plan pursuant to the NYSE inducement exception, Rule 303A.08.
Arcus Biosciences (NYSE:RCUS) will host a conference call and webcast on May 5, 2026 at 1:30 PM PT / 4:30 PM ET to discuss first-quarter 2026 financial results and pipeline updates for the quarter ended March 31, 2026.
Investors can join by phone (Meeting ID: 304747896), register online, or access a live webcast and slide presentation via the company’s Investors & Media website; a replay will be available after the live event.
Arcus Biosciences (NYSE:RCUS) announced inducement equity awards granted April 9, 2026: one new employee received options for 7,850 shares at an exercise price of $22.65 (closing price on April 8, 2026) and restricted stock units for 3,950 shares.
The awards were issued under the company’s 2020 Inducement Plan using the NYSE Rule 303A.08 inducement exception.
Arcus Biosciences (NYSE:RCUS) announced inducement equity awards for two new hires on March 24, 2026. The Compensation Committee granted options to purchase 7,050 shares at an exercise price of $21.41 (March 23, 2026 close) and 3,550 restricted stock units.
The awards were made under the company’s 2020 Inducement Plan pursuant to the NYSE Listed Company Manual Rule 303A.08 inducement exception.
Arcus Biosciences (NYSE:RCUS) announced inducement equity awards for two new employees on March 9, 2026. The Compensation Committee granted options to purchase 17,050 shares at an exercise price of $23.43 per share and 8,550 restricted stock units under the company’s 2020 Inducement Plan. The awards used the NYSE "inducement exception" (Rule 303A.08) and reflect hiring-related equity compensation for clinical-stage operations.
Arcus Biosciences (NYSE:RCUS) said its management team will participate in two investor conferences in Miami in March 2026: the Leerink Global Healthcare Conference on March 9 (fireside chat & 1x1s) and the Barclays 28th Annual Global Healthcare Conference on March 10 (1x1s).
A live webcast of the March 9 fireside chat will be available via the company’s Investors & Media website, with a replay posted after the event.
Arcus Biosciences (NYSE:RCUS) reported Q4 and full-year 2025 results and a pipeline update highlighting clinical progress for casdatifan and balance sheet strength. Casdatifan 100mg QD showed median PFS of 15.1 months and confirmed ORR of 45.2% (DCO Jan 30, 2026).
PEAK-1 Phase 3 is enrolling; a 1L registrational Phase 3 is planned by end-2026. Cash totaled $1.0 billion at year-end, supporting runway into at least H2 2028. Quemliclustat Phase 3 enrollment completed; results expected H1 2027.
Arcus Biosciences (NYSE:RCUS) reported updated ARC-20 results for casdatifan in late-line metastatic clear cell RCC. The 100mg QD tablet cohort showed mPFS 15.1 months and cORR 45% (DCO Jan 30, 2026). Pooled mPFS was 12.2 months with cORR 35%. Biomarker analysis linked sustained sEPO suppression to clinical benefit. No unexpected safety signals were observed; anemia-related discontinuations were 0% and hypoxia discontinuations were 3%.
Arcus Biosciences (NYSE:RCUS) will host a conference call and webcast on Feb 25, 2026 at 1:30 PM PT / 4:30 PM ET to discuss fourth-quarter and full-year 2025 financial results and a pipeline update.
Investors can join by phone (Access Code: 190500), register online, or view a live webcast and slide presentation on the company website; a replay will be available after the event.